IP Library › Granted Patent US 10,729,727
Granted Patent B2
US 10,729,727 · App. 16/204,936 · Granted Aug 4, 2020

Mesenchymal stem cells and uses therefor

Inventors: Sudeepta Aggarwal (North Potomac, MD); Mark F. Pittenger (Severna Park, MD); Timothy Varney (Baltimore, MD)
Assignee: Mesoblast International Sárl
A61K35/28A61K38/2026A61K38/2066A61K45/06C12N5/0662C12N5/0663C12N5/0664C12N5/0665C12N5/0666C12N5/0667C12N5/0668A61K2035/124Y02A50/409
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,729,727
App. No.
16/204,936
Granted
Aug 4, 2020
Kind
B2
Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims (23)

1. A method of treating an inflamed wound in a human in need thereof comprising administering isolated mesenchymal stem cells to the human in an amount effective to treat the inflamed wound, wherein the mesenchymal stem cells are genetically unmanipulated.

2. The method of claim 1 , wherein the wound is internal or external.

3. The method of claim 1 , wherein the wound is a dermal ulcer.

4. The method of claim 3 , wherein the dermal ulcer is caused by diabetes or sickle cell-anemia.

5. The method of claim 1 , wherein the mesenchymal stem cells are administered directly into the wound.

6. The method of claim 1 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium or on a dressing or reservoir.

7. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.

8. The method of claim 2 , wherein the mesenchymal stem cells are allogeneic.

9. The method of claim 6 , wherein the mesenchymal stem cells are allogeneic.

10. The method of claim 1 , wherein the mesenchymal stem cells are autologous.

11. The method of claim 2 , wherein the mesenchymal stem cells are autologous.

12. The method of claim 6 , wherein the mesenchymal stem cells are autologous.

13. The method of claim 1 , wherein the mesenchymal stem cells are harvested from a mesenchymal stem cell-containing tissue, isolated, and expanded in culture.

14. The method of claim 2 , wherein the mesenchymal stem cells are harvested from a mesenchymal stem cell-containing tissue, isolated, and expanded in culture.

15. The method of claim 6 , wherein the mesenchymal stem cells are harvested from a mesenchymal stem cell-containing tissue, isolated, and expanded in culture.

16. The method of claim 9 , wherein the mesenchymal stem cells are harvested from a mesenchymal stem cell-containing tissue, isolated, and expanded in culture.

17. The method of claim 13 , wherein the mesenchymal stem cell-containing tissue is blood, skin, cord blood, muscle, fat, perichondrium, bone marrow or periosteum.

18. The method of claim 14 , wherein the mesenchymal stem cell-containing tissue is blood, skin, cord blood, muscle, fat, perichondrium, bone marrow or periosteum.

19. The method of claim 15 , wherein the mesenchymal stem cell-containing tissue is blood, skin, cord blood, muscle, fat, perichondrium, bone marrow or periosteum.

20. The method of claim 16 , wherein the mesenchymal stem cell-containing tissue is blood, skin, cord blood, muscle, fat, perichondrium, bone marrow or periosteum.

21. The method of claim 1 , wherein the mesenchymal stem cells are administered in combination with an anti-inflammatory drug.

22. The method of claim 1 , wherein the mesenchymal stem cells promote angiogenesis.

23. The method of claim 1 , wherein the mesenchymal stem cells promote release of IL-10.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 051824/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 051824/0913 →
Cited By (4)
US 12,410,405 US 12,473,547 US 12,697,355 US 12,702,683